4-(2-Methyl-4,5,6,7-tetrahydroindol-1-yl)benzoic acid | 903146-93-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: 4-(2-Methyl-4,5,6,7-tetrahydroindol-1-yl)benzoic acid
• CAS: 903146-93-0
• 化学式: C₁₆H₁₇NO₂
• 分子量: 255.316
• InChiKey: HDHJNAVPYMMPIP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  42.2
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• TETRAHYDROINDOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS
  申请人：Page Patrick

  公开号：US20100120749A1

  公开（公告）日：2010-05-13

  The present invention is related to tetrahydroindole derivatives of Formula (I), pharmaceutical composition thereof, methods of preparation thereof and to their use for the treatment and/or prophylaxis of disorders or conditions related to Nicotinamide adenine dinucleotide phosphate oxidase (NADPH Oxidase).

  本发明涉及式（I）的四氢吲哚衍生物，其药物组成物，其制备方法以及它们用于治疗和/或预防与尼克酰胺腺嘌呤二核苷酸磷酸酰化酶（NADPH氧化酶）相关的疾病或症状的用途。
• Tetrahydroindole derivatives as NADPH Oxidase inhibitors
  申请人：GenKyo Tex

  公开号：EP2000176A1

  公开（公告）日：2008-12-10

  The present invention is related to tetrahydroindole derivatives of Formula (I), pharmaceutical composition thereof, methods of preparation thereof and to their use for the treatment and/or prophylaxis of disorders or conditions related to Nicotinamide adcninc dinucleotide phosphate oxidase (NADPH Oxidase).

  本发明涉及式（I）的四氢吲哚衍生物、其药物组合物、其制备方法及其用于治疗和/或预防与烟酰胺腺嘌呤二核苷酸磷酸氧化酶（NADPH 氧化酶）有关的疾病或病症。
• Small molecules for the modulation of MCL-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：US10000511B2

  公开（公告）日：2018-06-19

  This invention relates to compounds which selectively bind to the survival protein MCL-1 with high affinity and selectivity, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for modulating MCL-1 activity and for treating hyperproliferative disorders, angiogenesis disorders, cell cycle regulation disorders, autophagy regulation disorders, inflammatory disorders, and/or infectious disorders and/or for enhancing cellular engraftment and/or wound repair, as a sole agent or in combination with other active ingredients.

  本发明涉及以高亲和力和选择性与存活蛋白 MCL-1 选择性结合的化合物、含有此类化合物的药物组合物，以及使用这些化合物或组合物调节 MCL-1 活性和治疗过度增殖性疾病、血管生成疾病、细胞周期调节疾病、自噬调节疾病、炎症性疾病和/或感染性疾病和/或增强细胞移植和/或伤口修复，可作为单独制剂或与其他活性成分组合使用。
• Compositions and methods for enhancing proteasome activity
  申请人：President and Fellows of Harvard College

  公开号：US10351568B2

  公开（公告）日：2019-07-16

  Proteinopathies result from the proteasome not acting efficiently enough to eliminate harmful proteins and prevent the formation of the pathogenic aggregates. As described herein, inhibition of proteasome-associated deubiquitinase Usp14 results in increased proteasome efficiency. The present invention therefore provides novel compositions and methods for inhibition of Usp14, enhancement of proteasome activity and treatment of proteinopathies.

  蛋白病症是由于蛋白酶体不能有效地消除有害蛋白质并防止致病聚集体的形成。如本文所述，抑制蛋白酶体相关的去泛素化酶 Usp14 可提高蛋白酶体的效率。因此，本发明提供了抑制 Usp14、增强蛋白酶体活性和治疗蛋白质病的新型组合物和方法。
• RECA INHIBITORS AND THEIR USES AS MICROBIAL INHIBITORS OR POTENTIATORS OF ANTIBIOTIC ACTIVITY
  申请人：Cottarel Guillaume

  公开号：US20110015137A1

  公开（公告）日：2011-01-20

  The present invention provides RecA inhibitors, compositions containing them, systems for identifying or characterizing them, and methods of using them.